The verdict
Our read at a glance.
Whether anidulafungin is understood as an IV, hospital-use echinocandin antifungal for serious invasive Candida infections that works by blocking the fungal cell wall and is notably easy to dose because it is not cleared by the liver or kidneys, rather than a general or at-home antifungal.
- The signal
- In its pivotal trial anidulafungin performed at least as well as, and by some measures better than, fluconazole for invasive candidiasis and candidemia. Echinocandins as a class are now recommended first-line for many serious Candida infections, especially in critically ill patients and where azole resistance is a concern.
- The unknown
- The main worries are class-wide: echinocandin resistance is rising in some Candida species, including the emerging Candida auris, and the drug must be given by vein in a medical setting, so it is not an option for milder or outpatient fungal problems.
- Our read
- A clean, hospital-grade antifungal that hits a target humans do not have. Anidulafungin, an echinocandin, blocks the building of the fungal cell wall, works at least as well as fluconazole for serious Candida infections, and is unusually easy to dose because it is broken down in the blood rather than cleared by the liver or kidneys. Read it as an IV, inpatient drug for invasive fungal infection, not an oral or topical antifungal, with rising resistance in some species the main caveat.
The mechanism
How it works.
Fungal cells are wrapped in a wall stiffened by a mesh called beta-1,3-glucan, a material human cells do not make. Anidulafungin belongs to the echinocandins, drugs that block the enzyme (glucan synthase) that builds that mesh, so the wall weakens and the fungus, especially Candida yeast, dies. Because the target does not exist in people, the drug is selective and generally gentle. What sets anidulafungin apart from its relatives is how the body gets rid of it: instead of being processed by the liver or filtered by the kidneys, it slowly falls apart on its own in the bloodstream, so it usually needs no dose adjustment when those organs are struggling and has few interactions with other drugs. It has to be given by vein, because like other echinocandins it is not absorbed from the gut.
Safety & regulatory boundary
The consequential part.
Anidulafungin is generally very well tolerated; the main issues are histamine-related reactions if it is infused too quickly and uncommon liver-enzyme changes. It is given only by IV in a hospital or clinic for serious invasive Candida infections (bloodstream and deep-tissue) and esophageal candidiasis; it is not an oral or topical antifungal, does not treat superficial skin or nail fungus, and has no antibacterial activity. Because it is cleared by slow breakdown in the blood rather than by the liver or kidneys, it usually needs no dose change in organ impairment and has few drug interactions, but resistance in some Candida is rising and is monitored.
What's next
What we're watching.
Echinocandin resistance trends (including Candida auris), the role of newer long-acting echinocandins such as rezafungin and any oral echinocandin, and head-to-head positioning among the echinocandins.
Context
Why this is discussed.
Serious fungal infections that reach the bloodstream are dangerous and usually strike people who are already very ill. Anidulafungin is one of a small family of antifungals, the echinocandins, that attack a part of the fungal cell wall humans do not have, making them both effective and gentle, and it is the one cleared without relying on the liver or kidneys, which makes it easy to use in the sickest patients.
The evidence base
15 cited references.
Regulatory & labels2
Roerig (FDA label) · 2025
Roerig (FDA label) · 2024
Registered trials3
ClinicalTrials.gov · PHASE3 · TERMINATED · 2022-08-03
ClinicalTrials.gov · NOT_YET_RECRUITING · 2025-05-01
ClinicalTrials.gov · RECRUITING · 2012-09-21
Indexed literature (PubMed)10
Bilal H et al. · Virulence · 2022
Cabrera-Guerrero JP et al. · Pathogens · 2025
Cappelletty D et al. · Pharmacotherapy · 2007
Cortés L JA et al. · Rev Chilena Infectol · 2011
Murdoch D et al. · Drugs · 2004
Gupta AK et al. · Dermatol Clin · 2003
Erdem H et al. · Antimicrob Agents Chemother · 2025
Wang H et al. · Future Microbiol · 2016
Gobernado M et al. · Rev Esp Quimioter · 2008
Stan CD et al. · Rev Med Chir Soc Med Nat Iasi · 2014
Keep reading